Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Neurobiology of Opioid Dependence: 3 - 3

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000194
Recruitment Status : Withdrawn
First Posted : September 21, 1999
Last Update Posted : May 6, 2016
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Cycloserine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Masking: Double
Primary Purpose: Treatment
Official Title: Neurobiology of Opioid Dependence: 3
Study Start Date : January 1993
Actual Primary Completion Date : January 1998
Actual Study Completion Date : January 1998

Resource links provided by the National Library of Medicine

Drug Information available for: Cycloserine

Primary Outcome Measures :
  1. Behavioral, subjective, measures of naloxone-preci
  2. Phsyiological, neuroendocrine measures of naloxone

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00000194

Layout table for location information
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Layout table for investigator information
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System

Layout table for additonal information
Responsible Party: Yale University Identifier: NCT00000194    
Other Study ID Numbers: NIDA-00191-3
K20DA000191 ( U.S. NIH Grant/Contract )
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: May 6, 2016
Last Verified: August 2015
Keywords provided by Yale University:
opioid disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Molecular Mechanisms of Pharmacological Action